Product Information
RHOFADE 1% CREAM is a brand product labeled by EPI Health, LLC, priced at $22.5013 per GM under NDC 71403000330. Its NADAC has been published 232 times since May 19, 2021.
FDA first approved this application on Jan 18, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the OXYMETAZOLINE HYDROCHLORIDE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 g/100g
Manufacturer
EPI Health, LLCNDC
71403000330
Classification
Brand
Dosage Form
CREAM
Route
TOPICAL
Effective Date
10/22/2025
Active Ingredients
OXYMETAZOLINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA208552FDA Approved
1/18/2017
TE Code
AB
On Market Since
1/18/2021
Pharmacological Classes
Price Statistics
The NADAC for RHOFADE 1% CREAM has been published 232 times since May 19, 2021, and over the history we have for it it has risen 29.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $22.5013 per GM |
|---|---|
| All-time high | $23.4846 (Jul 16, 2025) |
| All-time low | $17.3326 (May 19, 2021) |
| 52-week high | $22.5013 |
| 52-week low | $22.3808 |
| Median price | $18.2565 |
| Average price | $19.5297 |
| Largest weekly change | +9.0% (Feb 12, 2025) |
| Weeks tracked | 232 |
| Tracking since | May 19, 2021 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
+0.5%
3Y
+14.0%
5Y
+29.8%
All
+29.8%
Last surveyed Oct 22, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the OXYMETAZOLINE HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
EPI Health, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXYMETAZOLINE HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Vasoconstrictor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RHOFADE 1% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for RHOFADE 1% CREAM, manufactured by EPI Health, LLC, is $22.5013 per GM (NDC 71403000330), effective Oct 22, 2025.
How has the price of RHOFADE 1% CREAM changed over time?
Over the history we have for it, the NADAC for RHOFADE 1% CREAM has risen 29.8%. It has been tracked across 232 weekly CMS publications since May 19, 2021.
What are the highest and lowest recorded NADAC prices for RHOFADE 1% CREAM?
Since May 19, 2021, the NADAC for RHOFADE 1% CREAM has ranged from a low of $17.3326 (May 19, 2021) to a high of $23.4846 (Jul 16, 2025), with a median of $18.2565 per GM.
Are there cheaper alternatives to RHOFADE 1% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of RHOFADE 1% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RHOFADE 1% CREAM?
RHOFADE 1% CREAM (NDC 71403000330) is labeled by EPI Health, LLC, and CMS classifies it as a brand product.